Blueprint Medicines Announces FDA Approval Of AYVAKIT For Treatment Of Adults With Unresectable Or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

Benzinga · 01/09/2020 20:53